ADRX-0706 is under clinical development by Adcentrx Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADRX-0706’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADRX-0706 overview
ADRX-0706 is under development for the treatment of solid tumors, urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer, cervical cancer, ovarian cancer, non-small cell lung cancer (NSCLC) and pancreatic cancer. The drug candidate is an antibody drug conjugate (ADC) comprising of a novel fully human IgG1 antibody targeting human Nectin-4 linked to a novel tubulin inhibitor payload, AP052, through i-Conjugation technology using a cleavable linker and stable conjugation chemistry. It is administered through intravenous route.
Adcentrx Therapeutics overview
Adcentrx Therapeutics is a biotechnology company that focuses on protein conjugate therapeutic development for cancer and other life-threatening diseases. The company combines the targeting precision of biologics and the disease-fighting power of small molecule payloads. Its product pipeline includes the ADRX104 oncology drug program; and the ADRX863 Immunology drug program at clinical stages among others. Adcentrx Therapeutics is also investigating another drug program for multiple oncology indications. The company operates with an additional office in Shanghai, China. Adcentrx Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of ADRX-0706’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
